

D-SERINE TRANSPORT ANTAGONIST FOR TREATING PSYCHOSIS

Related Application

The present application is a continuation-in-part of U.S. Application Serial No. 09/365,889 filed August 3, 1999.

5 Background

Schizophrenia is a psychotic disorder associated with positive, negative and cognitive symptoms, neuropsychological deficits and poor social functioning. Traditional theories of schizophrenia have focused on abnormal dopaminergic neurotransmission. Mainstay treatments for schizophrenia including use of typical (e.g., thiorazine, haloperidol) or atypical (e.g. clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazol, sertindole) antipsychotics (also called neuroleptics or major tranquilizers). Antipsychotics may be administered orally, parenterally and in depot formulations. In addition, patients may be treated with mood stabilizers (e.g., lithium, valproic acid), antidepressants (e.g., tricyclics, SSRIs), or antianxiety agents (e.g., benzodiazepines, barbiturates). Recent theories postulate that schizophrenia is associated with dysfunction or dysregulation of neurotransmission mediated at brain *N*-methyl-D-aspartate (NMDA)-type glutamate receptors (Javitt, 1987; Javitt and Zukin, 1991). PCP and other psychotomimetic drugs mediate their effects by blocking NMDA receptor-mediated neurotransmission. NMDA agonists, including glycine and D-serine, reverse the behavioral effects of PCP in rodents (Toth et al., 1986; Javitt and Frusciante, 1997; Javitt et al., 1997; Tani et al., 1994, 1991; Nilsson et al., 1997), and induce significant improvement in negative and cognitive symptoms in remitted schizophrenics (Javitt et al., 1994; Heresco-Levy et al, 1999; Tsai et al., 1998), supporting the PCP/NMDA model of schizophrenia.

Both glycine and D-serine serve as endogenous modulators of NMDA receptors (Hashimoto et al., 1995; Hashimoto and Oka, 1997). In general, amino acid levels in brain are regulated by endogenous transporters that limit CNS levels. A potential alternate approach to increasing glycine or D-serine levels in brain, therefore, would be the use of agents that inhibit either glycine or D-serine transport in brain. This approach has been well described in the case of glycine. Glycine (GlyT1) transporters in brain are well described and have been shown to be colocalized with NMDA receptors (Smith et al., 1992; 1992; Liu et al., 1993). Further, modulation of glycine transporters has been shown to modulate NMDA receptor-mediated neurotransmission both in vitro and in vivo (Javitt and Frusciante, 1997; Javitt et al., 1997; Supplison and Bergman, 1998; Bergeron et al, 1998; Berger et al, 1998; Danysz and Parsons, 1998), supporting the physiological relevance of amino acid transport processes.

The present invention relates to the use of D-serine transport inhibitors (also referred to as uptake antagonists) in the treatment of schizophrenia. D-Serine, like glycine, has been shown to be effective in treatment of persistent negative symptoms of schizophrenia (Tsai et al., 1998). However, as with glycine, sufficient concentrations of D-serine are already present in brain that NMDA/glycine sites (the molecular target of D-serine) would be saturated under normal circumstances (Hashimoto et al., 1995, Hashimoto and Oka, 1997; Matsui et al., 1995). If the NMDA/glycine site were saturated by endogenous D-serine, then neither exogenous glycine or exogenous D-serine would have significant neurochemical or behavioral effects since both these agents share a common target (i.e., the NMDA/glycine site). The fact that glycine and serine do potentiate NMDA receptor-mediated neurotransmission suggests that for D-serine, as with glycine, there must be an endogenous process that “protects” NMDA receptors from extracellular D-serine. At present, D-serine transport processes in brain are poorly understood. The present application describes a novel brain D-serine transport system that is relatively selective for D-serine over other amino acids, and provides the first

demonstration that agents which block D-serine transport in vitro also stimulate NMDA receptor in vivo and are effective in animal models of schizophrenia.

The next section describes state-of-the-art regarding existence of D-serine transport systems in brain. Example 1 describes the existence of multiple high affinity D-serine transport systems in synaptosomal membranes that can be differentiated based upon sensitivity to inhibition by alanine. Example 2 describes the relative ability of three amino acid derivates, glycine dodecylamide (GDA), D-serine dodecylamide (D-Ser DA) and D-alanine dodecylamide (D-Ala DA) on amphetamine- and PCP-induced locomotor activity in rodents. These findings demonstrate likely effectiveness of D-serine transport inhibitors in treatment of persistent negative and cognitive symptoms in schizophrenia and treatment of related symptoms in other neurological and psychiatric disorders associated with reduced NMDA function including but not limited to Alzheimers disease, age associated memory impairment, autism, attention-deficit deficit disorder, bipolar disorder, depression, Parkinsons disease, Huntingtons disease, and recovery from stroke, neurological insult or closed head injury. Example 3 demonstrates effects of the amino acid glycine and the amino acid derivative D-Ala DA on in vivo [3H]MK-801 binding, an in vivo model of NMDA receptor activation.

Detailed Description of the Invention

Brain is known to contain multiple amino acid transport systems, including system "Gly", which is specialized for uptake of glycine, system "A" which is specialized for uptake of Alanine, system "L" which is specialized for uptake of Leucine, and system "ASC" which is specialized for uptake of Alanine, Serine and Cysteine (Sershen and Lajtha, 1979; Hashimoto and Oka, 1997). Serine transport, including transport of both L- and D-isomers of serine, is generally considered to occur via system ASC (Hashimoto and Oka, 1997), although transport may also occur though system L (Sershen and Lajtha, 1979). The hallmark of this system is high affinity for alanine. Two ASC-like transporters have recently been cloned and have been termed ASCT1 (Arriza et al., 1993) and

ASCT2 (Utsunomiya-Tate et al., 1996). Studies with cloned transporters have confirmed that ASC-family transporters show highest affinity for L-alanine, along with high affinity for L-cysteine and L-serine, and stereoselectivity for L- vs. D-amino acids. A related transporter, termed SATT was found to have differential affinity for serine and cysteine. However, this transporter was found not to be sensitive to D-serine (Shafqat et al., 1993). Based on the relatively low affinity of these transporters for D-amino acids, Hashimoto et al. (1997) concluded that “further study is needed to clarify a specific transport system for D-serine in mammals.”

D-Serine transport has also been studied in glioma cells (Hayashi et al., 1997) and astocyte cultures (Schell et al., 1995). Glia have also been shown to accumulate exogenously administered D-serine in vivo (Wako et al., 1995; Schell et al., 1995). Transport in these cells, like transport through cloned receptors, was found to be inhibited most strongly by L-cysteine, L-alanine, and L-serine. D-Serine was transported, but affinity for D-serine was approximately 20-fold lower than affinity for L-serine. This finding is consistent with glial D-serine uptake being mediated by system ASC transporters. The relative insensitivity of these transporters to D-serine makes it unlikely that they regulate synaptic D-serine levels in vivo.

Further suggestion that additional D-serine transporters are present in brain comes from a study by Tanii et al. (1994). In that study, they observed that intracerebroventricularly administered D-alanine was significantly more potent in reversing PCP-induced hyperactivity than was intracerebroventricularly administered D-serine, even though D-serine is more potent in binding to the NMDA/glycine site. This finding suggests the existence of a brain transporter with higher affinity for serine and alanine. Such a pattern would be opposite to the known selectivity pattern of system ASC. In discussing relative potency of D-serine to other amino acids, Tanii et al. (1994) postulated the existence of “specific metabolizing systems” for D-serine, but did not specifically postulate the existence of a selective transporter. Moreover, despite the recognition that D-serine serves as an

endogenous agonist of NMDA receptors, use of selective D-serine transport antagonists in the treatment of schizophrenia has not been previously suggested.

For this study, two novel amino acid derivatives were synthesized – D-serine dodecylamide (D-Ser-DA) and D-alanine dodecylamide (D-Alanine-DA). Synthesis was performed by addition of an alkyl group to the C-terminus (COOH or equivalent) of the amino acid by amide linkage.

Variations of this approach, wherein other hydrophobic groups are linked to either the C- or N-terminus (NH₂ or equivalent) of glycine, D-serine, D-alanine, L-serine or L-alanine, are obvious extensions of this invention. Such groups would include but not be limited to alkyls (C1-C13) such as methyl, phenyls or phenylalkyls (C1-C13), cyano, halogen such as fluoro or halalkyl (C1-C13) such as fluoromethyl groups.

Example 1

Based upon the observation that glycine is effective in the treatment of schizophrenia (Javitt and Zukin, US patent 5,854,286), it can be concluded that glycine sites are not saturated under normal physiological conditions in schizophrenia. Extracellular concentrations of D-serine in brain are known to be above those necessary to saturate NMDA/glycine sites. These findings raise the possibility that brain may contain a D-serine transporter that protects NMDA receptors from extracellular D-serine concentrations. Actions of such a transporter would be analogous to the role played by glycine transporters in protecting NMDA receptors from extracellular glycine levels. Use of glycine transport inhibitors in treatment of schizophrenia were described in a separate application (Javitt, US patent 5,837,730). The present application demonstrates the existence of a novel D-serine transporter, supporting the feasibility of use of D-serine transport inhibitors in treatment of schizophrenia.

In order to investigate the existence of a synaptosomal D-serine transporter, synaptosomal (P2) preparations were prepared from rodent brain. This preparation permits identification of transport mechanisms on pre- and post-synaptic terminals and so is crucial for identifying systems that may be co-localized with NMDA receptors which are located on synaptic terminals. In contrast, the majority of transport studies are performed using either cloned transporters or brain slices, which provide less specificity for identifying perisynaptic transport mechanisms. An obvious extension of the present invention, however, is use of an assay system in which the D-serine transporter is cloned and expressed in a suitable expression system. Methods for cloning would include but not be limited to derivation of mRNA from rodent or human brain, including postmortem human brain tissue, or from other suitable brain tissue or from other tissues expressing D-serine transporters, and progressive fractionation of such mRNA until relevant sequences are obtained, or from expression libraries derived from rodent, primate or other appropriate sources, or from cell lines expressing D-serine transporters. Cloned transporters would be expressed in a suitable expression system including, but not limited to, *Xenopus* oocytes, or immortalized cells derived from mammalian, reptilian or avian sources. Obvious extensions would also be use of brain slices, use of cell culture lines which express D-serine transporters or primary culture of neurons.

Synaptosomal (P2) preparations were prepared from brains of Sprague-Dawley rats (200-250 g) using the method of Debler and Lajtha (1987). Rodents were decapitated and brains (cortex + hippocampus) were homogenized in 0.32 M sucrose buffered to pH 7.4 with Tris-HCl. Homogenate was centrifuged at 1000 g for 12 min at 4 °C. The supernatant was centrifuged at 14,000 g 12 min and the P2 pellet was resuspended in Krebs solution (pH 7.4) containing 124 mM NaCl, 26 mM NaHCO₃, 10.5 mM glucose, 5 mM KCl, 1.3 mM MgSO₄, 1.2 mM KH₂PO₄, and 2.4 mM CaCl₂. For uptake studies, membranes were incubated at 37°C in the presence of L- or D-[³H]serine, as appropriate. L- and D-[³H]Serine were obtained from DuPont-NEN (Natick, MA) and had specific

activities of 25.4 and 19.7 Ci/mM, respectively. Incubation was terminated by filtration under reduced pressure through Whatman GF/B filters, rinsing twice with 5 ml ice-cold buffer.

For initial kinetic studies, incubations were conducted at 6 time points between 1 and 30 min.

Non-specific binding was determined in the presence of 30 mM L- or D-serine. For inhibition studies,

5 L-alanine, L-cysteine, L-serine, and D-serine were tested at 6 concentrations between 0.03 and 10 mM. Control uptake levels were defined as uptake levels in the absence of added L-alanine, L-

cysteine, L-serine, or D-serine. % control binding was defined as level of uptake in the presence of specified concentrations of antagonist divided by uptake under control conditions, expressed as a

percent. 1 mM concentrations of HA-966, L-trans-pyrrolidine-2,4-dicarboxylic acid (L-PDC),

10 nipecotic acid, 2-aminobicyclo (2,2,1)heptane-2 carboxylic acid (BCH) and methylaminoisobutyric acid (MeAIB) and 10 mM sarcosine were added to the homogenate to prevent binding to NMDA-

associated glycine binding sites, and potential uptake via glutamate, GABA, system L, system A and system GLY transporters, respectively. Incubations were terminated following 30 min. For both

kinetic and inhibition studies, non-specific binding was determined in the presence of 30 mM D- or L-
15 serine, as appropriate.

For saturation studies, L- and D-serine were added at 12 concentrations between .01 and 5

mM. Assays were conducted at 37 °C. Non-specific binding was determined at 0 °C. Incubations were terminated following 5 min. Assays were conducted in the presence of 30 mM L-alanine to

prevent uptake through system ASC, along with 1 mM concentrations of HA-966, L-PDC, nipecotic
20 acid, BCH and MeAIB. Km values were determined by non-linear regression to a single rectangular,

3 parameter hyperbolic function using Sigmaplot 2000 (SPSS Inc., Chicago, IL). Data in text

represent mean ± sem. Statistical comparisons were performed using two-tailed Student's *t* statistic.

For initial studies, uptake was measured over a 30 min. period (Fig. 1). Uptake of L- and D-
[³H]serine was linear over the first 10 min. with a tendency for plateau by 30 min. Uptake was
unaffected by incubation with the selective system L antagonist BCH (10 mM). Effects of the system
ASC substrates alanine, cysteine and serine were evaluated at concentrations between .03 and 30 mM
(Figure 2). Complete inhibition of serine uptake was obtained with either L- or D-serine. In both
cases, L-serine showed greater potency than D-serine in inducing inhibition. Inhibition was also
obtained with cysteine, although potency of cysteine was significantly less than that of either L- or D-
serine. In contrast, only partial inhibition was observed with alanine, even at doses as high as 30
mM. This pattern of inhibition is opposite to that of system ASC, indicating that the observed L- and
D-serine uptake is mediated primarily by a system other than system ASC. This system has not been
previously described.

Finally, in order to characterize kinetics of uptake, saturation studies were conducted
following 5 min. incubation with concentrations of L- and D-serine between 0.01 and 5 mM (Figure
3). Studies were conducted in the presence of 30 mM L-alanine to prevent uptake through system
ASC. Even in the presence of alanine, significant uptake of L- and D-serine was observed.
Saturation of D-serine binding was observed between 3 and 5 mM, with half-maximal binding
occurring between 1-2 mM. A Michaelis-Menton constant (K_m) of 3.33 mM was obtained by non-
linear regression. An Eadie-Hofstee plot demonstrated linear uptake, supporting the concept that this
uptake occurs via a discrete, alanine-insensitive D-serine transport system with approximately equal
affinity for D- and L-serine. The presence of such a system in synaptosomal tissue from rodent
forebrain indicates that it may play a crucial role in regulation of D-serine concentrations in the
vicinity of NMDA receptors. Inhibition of this system would be expected to increase local D-serine
concentrations in brain, leading to augmentation of NMDA receptor-mediated neurotransmission.

Inhibition of selective serine uptake would thus constitute a novel mechanism for stimulation of NMDA receptor-mediated neurotransmission in vivo.

In summary, the present example demonstrates the existence of multiple transport systems for D-serine in P2 synaptosomal membranes which can be distinguished based upon sensitivity to inhibition by alanine.

Example 2

We have previously reported ability of the glycine derivative glycyldodecylamide (GDA) to inhibit synaptosomal glycine transport. This study evaluated the ability of two novel amino acid derivatives D-serine dodecylamide (D-Ser-DA) and D-alanine dodecylamide (D-Ala-DA) to inhibit glycine and D-serine uptake in vitro and to affect rodent activity in vivo. Effects of these agents on synaptosomal glycine and D-serine transport were determined using assay methods described previously in Javitt and Frusciante, 1997 and in Example 1, above. The amino acid derivatives were then evaluated in a rodent behavioral model that assesses locomotor hyperactivity following administration of either the dopamine releasing agent amphetamine or the NMDA antagonist PCP. Atypical antipsychotics and agents that potentiate NMDA receptor mediated neurotransmission are more effective in modulating effects of PCP than of amphetamine. The relationship between ability to antagonize D-serine transport in vitro and to modulate PCP-induced hyperactivity in vivo was then assessed.

Effects of amino acid derivatives on glycine and D-serine uptake are shown in Table 1. As shown previously (Javitt and Frusciante, 1997), GDA significantly inhibited glycine uptake into synaptosomes. Similar effects were shared by DSDA whereas DADA was ineffective. GDA also significantly inhibited D-serine uptake into synaptosomes at concentrations similar to those used to inhibit glycine transport. Similar effects were shared by DADA but not DSDA.

To assess effectiveness of these agents in modulating NMDA receptor-mediated neurotransmission, amphetamine and PCP-induced was evaluated in absence and presence of these agents. Assays were conducted using methods of Javitt et al. (1997). Mice (C57) were acclimated to automatic test chambers. As opposed to BALB/c mice which were used in prior studies, C57 mice were used for the present study because they are known to have relatively little spontaneous hyperactivity in response to PCP. Such mice are thus more similar to primates that have a predominant reduction in activity in response to PCP. Therefore, in C57 mice, as in primates, it is predicted that the prominent behavioral response to NMDA agonists would be a decrease in activity following amphetamine administration and an increase in activity following PCP administration.

Baseline activity was monitored for 30 min. Animals were then pretreated with saline, GDA, D-Ser-DA or D-Ala-DA and activity was monitored for an additional 15 min. All drugs were administered at a dose of 1.6 mg/kg. Finally, animals were challenged with amphetamine (1 mg/kg) or PCP (3 mg/kg). Distance traveled (cm) per min (DT) was used as the primary dependent measure.

All agents produced a numerical reduction in amphetamine-induced activity and increase in PCP-induced activity, suggesting similar effects by both glycine and D-serine transport inhibitors. For statistical analysis, data were collapsed across treatments associated with D-serine transport inhibition (GDA, DADA) vs. those not associated with inhibition (saline, D-Ser-DA). A 2 X 2 ANOVA evaluated alteration in amphetamine vs. PCP induced hyperactivity by agents associated with D-serine transport inhibition vs. those not associated with serine transport inhibition. A significant amphetamine/PCP X serine transport inhibitor interaction effects was observed ($F=4.82$, $df=1/60$, $p=.03$), reflecting ability of D-serine transport inhibitors to both decrease amphetamine-induced hyperactivity and reverse PCP-induced hypoactivity. The ability of D-serine transport inhibitors to modulate amphetamine and PCP induced effects suggests effectiveness of these agents in treatment of neuropsychiatric illness.

Example 3

An additional assay system that has been shown to be sensitive to effects of NMDA agonists is in vivo [^3H]MK-801 binding (Murray et al., 2000). Consequently, the in vivo [^3H]MK-801 binding system, therefore, was used to evaluate effects of glycine site agonists and antagonists on NMDA activation in vivo. To implement this protocol, mice (C57) were pretreated with either saline, glycine (1.6 g/kg) or D-Ala-DA (16 mg/kg) administered i.p. Animals used for “nonspecific” in vivo binding were then administered unlabelled MK-801 (3 mg/kg) by retroorbital injection whereas animals used for “total binding” were administered saline. Both “nonspecific” and “total binding” animals then received [^3H]MK-801 (200 $\mu\text{Ci/kg}$, 28.9 Ci/mmol) by retroorbital injection. “Specific” binding to NMDA receptors was defined as the difference between “total binding” and “nonspecific.” Following 10 min, animals were sacrificed. Brains were removed and homogenized in 40 vol/w buffer. 500 μl aliquots were then filtered in triplicate under reduced pressure through Whatman GF/B filters. [^3H]MK-801 levels were determined by liquid scintillation. It has previously been demonstrated by others that treatment with NMDA agonists increases including D-serine increases specific binding to NMDA receptors in vivo whereas treatment with glycine site antagonists decreases specific binding (Murray et al., 2000).

In this experiment, specific binding under control conditions was 990 ± 2766 DPM/500 μl homogenate ($n=3$). Under control conditions, difference between total and nonspecific was not significant given the small n , indicating low levels of NMDA activation under control conditions. Pretreatment with glycine increased specific binding by 15% to 1133 ± 1455 DPM/500 μl homogenate. Under these circumstances, the difference between nonspecific and total binding was specific at trend level ($p=.1$, one tail). However, the level of specific binding following glycine treatment was not significantly greater than control levels. Treatment with D-Ala-DA led to a 250% increase in specific binding to 3888 ± 1734 DPM/500 μl homogenate. In the presence of D-Ala-DA,

total binding was significantly higher than non-specific indicating substantial NMDA activation (p=.015, one tail). Further, there was a significant trend toward increased specific binding following D-Ala-DA than under control conditions (p=.1, one tail). These findings support the concept that agents that activate the glycine site either directly (e.g., glycine, D-serine) or by inhibition of glycine or D-serine transport (e.g., D-Ala-DA) potentiate NMDA receptor-mediated neurotransmission in vivo.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Table 1: Inhibition of glycine and D-serine uptake by glycyldodecylamide (GDA), D-serine dodecylamide (D-Ser-DA) and D-alanine dodecylamide (D-Ala-DA). Values represent percent control uptake in the presence of specified concentration of antagonist. Data are mean of 3 separate experiments each performed in triplicate

Compound	Concentration (μ M)	Glycine uptake		T Value	P value	D-serine uptake		T Value (df=2)	P value
		Average	Std. Dev.			Average	Std. Dev.		
GDA	1	99.2	6.1	0.24	0.8	95.1	9.46	0.89	0.5
	10	99.7	6.3	0.07	0.9	102.4	5.33	-0.78	0.5
	25	88.1	3.2	6.41	0.02	104.0	1.44	-4.83	0.04
	50	70.7	9.2	5.52	0.03	97.4	6.62	0.69	0.6
	100	41.5	2.6	38.36	0.0007	77.6	3.08	12.6	0.006
	200	31.6	1.9	61.95	0.0003	60.9	6.82	9.91	0.01
	500	24.4	4.4	29.90	0.001	47.6	1.98	45.9	0.0005
D-SER-DA	1	90.9	4.7	3.33	0.08	95.2	8.0	4.09	0.4
	10	83.5	4.8	5.94	0.03	100.6	7.5	0.07	0.9
	25	60.2	12.1	5.70	0.03	97.0	8.5	3.64	0.6
	50	42.0	17.5	5.73	0.03	96.7	9.5	13.3	0.6
	100	24.1	15.4	8.57	0.02	96.4	19.2	7.65	0.8
	200	13.7	16.4	9.12	0.02	105.9	44.7	5.30	0.8
	500	10.2	12.9	12.09	0.007	83.5	21.7	3.85	0.3
D-ALA-DA	1	101.9	11.0	-0.30	0.8	94.9	4.0	0.41	0.2
	10	98.9	11.7	0.16	0.9	101.4	5.9	-0.89	0.7
	25	92.5	16.4	0.79	0.5	93.3	8.1	-0.85	0.3
	50	83.4	32.3	0.89	0.5	86.2	4.0	0.47	0.03
	100	79.3	51.1	0.70	0.6	67.1	5.5	0.43	0.009
	200	70.7	51.5	0.99	0.4	51.3	17.2	-0.26	0.04
	500	67.8	53.4	1.04	0.4	44.1	2.8	1.51	0.0009

Table 2: Effect of amino acid derivatives on rodent activity levels following amphetamine (1 mg/kg) or PCP (3 mg/kg) challenge. DT=distance traveled. n=8 per group

Condition	Baseline		Pretreatment		Amph/PCP challenge	
	DT (cm)	Std dev	DT (cm)	Std dev	DT (cm)	Std dev
<i>Amphetamine treatment</i>						
Saline	69.0	46.4	69.0	49.7	211.3	141.4
GDA	52.5	31.1	53.4	52.5	207.9	97.8
D-Ser-DA	60.6	44.6	103.2	91.8	196.2	100.1
D-Ala-DA	48.3	36.6	48.0	35.3	100.3	77.9
<i>PCP treatment</i>						
Saline	41.4	27.6	85.6	58.9	91.5	51.0
GDA	51.3	64.2	77.2	72.5	132.6	69.0
D-Ser-DA	59.2	63.0	59.2	27.6	108.2	48.3
D-Ala-DA	64.5	41.1	83.2	47.3	149.2	66.2

Variations of the invention will be apparent to the skilled artisan.

References

Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of N-methyl-D-aspartate receptor function by glycine transport. *Proc Natl Acad Sci U S A*. 1998;95:15730-4.

Danysz W, Parsons CG. Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications. *Pharmacol. Rev.* 1998;50:597-664.

Debler EA, Lajtha A (1987): High-affinity transport of gamma-aminobutyric acid, glycine, taurine, L-aspartic acid, and L-glutamic acid in synaptosomal (P2) tissue: a kinetic and substrate specificity analysis. *J Neurochem* 48:1851-6.

D'Souza DC, Charney D, Krystal J (1995): Glycine site agonists of the NMDA receptor: a review. *CNS Drug Revs* 1:227-260.

Hashimoto A, Oka T, Nishikawa T (1995): Extracellular concentration of endogenous free D-serine in the rat brain as revealed by in vivo microdialysis. *Neuroscience* 66:635-643.

Hashimoto A, Oka T (1997): Free D-aspartate and D-serine in the mammalian brain and periphery. *Prog. Neurobiol* 52:325-353.

Heresco-Levy U, Javitt DC, Irmilov M, Mordel C, Horowitz A, Kelly D (1996): Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. *Br J Psychiatry* 169:610-617.

Javitt DC, Sershen H, Hashim A, Lajtha A (1997): Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake antagonist glycyldodecylamide.

Neuropsychopharmacol 17:202-204.

Javitt DC, Frusciante MJ. (1997): Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: Implications for schizophrenia and substance abuse. *Psychopharmacol.* 129: 96-98.

Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994):

30 Amelioration of negative symptoms in schizophrenia by glycine. *Am J Psychiatry* 151:1234-1236.

Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. *Am J Psychiatry* 148:1301-8.

Javitt DC, Zukin SR (1989): Interaction of [³H]MK-801 with multiple states of the *N*-methyl-D-aspartate receptor complex of rat brain. *Proc. Nat. Acad. Sci. USA* 86:740-744.

Javitt DC (1987): Negative schizophrenic symptomatology and the phencyclidine (PCP) model of schizophrenia. *Hill J Psychiat* 9:12-35.

Kleckner NW, Dingledine R (1988): Requirement for glycine in the activation of NMDA-receptors expressed in *Xenopus* oocytes. *Science* 241:835-837.

40 Leiderman E, Zylberman I, Javitt DC, Zukin SR, Cooper TB. Effect of high-dose oral glycine on serum levels and negative symptoms in schizophrenia. *Biol. Psychiatry*, in press.

Liu QR, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson N (1993): Cloning and expression of spinal cord- and brain-specific glycine transporter with novel structural features. *J Biol Chem* 268:22802-8.

45 Matsui T, Sekiguchi M, Hashimoto A, Tomita V, Nishikawa T, Wada K (1995) Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. *J Neurochem.* 65:454-458.

McBain CJ, Kleckner NW, Wyrick S, Dingledine R (1989): Structural requirements for the glycine coagonist site of N-methyl-D-aspartate receptors expressed in *Xenopus* oocytes. *Mol Pharmacol* 36:556-565.

Murray F, Kennedy J, Hutson PH, et al (2000): Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro. *Eur J Pharmacol* 397:263-70.

Reynold IJ, Murphy SN, Miller RJ (1987): 3H-labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. *Proc. Natl. Acad. Sci. USA* 84:7744-7748.

Schell MJ, Molliver ME, Snyder SH (1995). D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. *Proc. Natl. Acad. Sci. USA* 92:3948-3952.

Sershen H, Latha A (1995): Inhibition pattern by analogs indicates the presence of ten or more transport systems for amino acids in brain cells. *J Neurochem* 32:719-726.

Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL (1992): Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. *Neuron* 8:927-35.

Supplisson S, Bergman C (1997): Control of NMDA receptor activation by a glycine transporter co-expressed in *Xenopus* oocytes. *J Neurosci* 17:4580-90.

Tanii Y, Nishikawa T, Hashimoto A, Takahashi K (1991): Stereoselective inhibition by D- and L-alanine of phencyclidine-induced locomotor stimulation in the rat. *Brain Res* 563:281-284.

Tanii Y, Hishikawa T, Hashimoto A, Takahashi K (1994): Stereoselective antagonism by enantiomers of alanine an dserien of phencyclidine-induced hyperactivity, stereotypy and ataxia. *J. Pharmacol. Exp. Ther.* 269:1040-1048.



70 Tsai G, Yang P, Chung L-C, Lange N, Coyle JT (1998): D-serine in the treatment of schizophrenia. Biol. Psychiatry 44:1081-1089.

Wood PL (1995): The co-agonist concept: is the NMDA-associated glycine receptor saturated in vivo? Life Sci 57:301-10.

75 Wong EH, Knight AR, Ransom R (1987) Glycine modulates [3H]MK-801 binding to the NMDA receptor in rat brain. Eur J Pharmacol 142:487-8.

Zafra F, Aragon C, Olivares L, Danbolt NC, Gimenez C, Storm-Mathisen J (1995): Glycine transporters are differentially expressed among CNS cells. J Neurosci 15:3952-69

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
21